RxDoctor Payments Data

Joel Palefsky, MD

Infectious Disease · San Francisco, CANPI 1336191345

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Merck accounts for 79.0% of it on its own, with 6 other manufacturers making up the rest. Among infectious disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$68,299in general payments, 2019–2025

Across 88 payments — averaging $776.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$54K
  • Roche Diagnostics Corporation$6K
  • GSK$4K
  • Theratechnologies Inc.$3K
  • Ventana Medical Systems, Inc.$1K
  • Janssen Scientific Affairs, LLC$550
  • plus $142 from 1 others
$235,764in research payments, 2019–2025

Across 13 payments — averaging $18,136 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Roche Molecular Systems, Inc.$150K
  • Merck$74K
  • Bausch Health US, LLC$11K

What the payments were for

  • Consulting fees$33,43849%
  • Speaking & faculty fees$13,33020%
  • Grants$5501%
  • Travel & lodging$19,17728%
  • Food & beverage$1,8043%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,299 in reported general payments places this provider in the 95th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$12,470
Medicare patients
53
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →